Purple Biotech Ltd Asset Resilience Ratio
Purple Biotech Ltd asset resilience ratio. Purple Biotech Ltd (KTOV) has an Asset Resilience Ratio of 0.01% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KTOV cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Purple Biotech Ltd (2016–2019)
Asset resilience ratio of Purple Biotech Ltd from 2016 to 2019. This chart shows how Purple Biotech Ltd's Asset Resilience Ratio has changed over time. Read Purple Biotech Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Purple Biotech Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Purple Biotech Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA10.00K | 0.01% |
| Total Liquid Assets | ILA10.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Purple Biotech Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Purple Biotech Ltd Industry Peers by Asset Resilience Ratio
Compare Purple Biotech Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 37.11% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
Purple Biotech Ltd Asset Resilience Ratio by Year (2016–2019)
Purple Biotech Ltd asset resilience ratio by year from 2016 to 2019. The table below shows the annual Asset Resilience Ratio data for Purple Biotech Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 13.66% | ILA2.01 Million ≈ $5.39K |
ILA14.72 Million ≈ $39.46K |
+3.33pp |
| 2018-12-31 | 10.33% | ILA1.52 Million ≈ $4.08K |
ILA14.72 Million ≈ $39.47K |
-14.26pp |
| 2017-12-31 | 24.59% | ILA3.49 Million ≈ $9.35K |
ILA14.18 Million ≈ $38.02K |
-28.37pp |
| 2016-12-31 | 52.96% | ILA7.90 Million ≈ $21.18K |
ILA14.91 Million ≈ $39.98K |
-- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more